icon-    folder.gif   Conference Reports for NATAP  
  18th CROI
Conference on Retroviruses
and Opportunistic Infections
Boston, MA
February 27 - March 2, 2011
Back grey_arrow_rt.gif
Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
  Reported by Jules Levin
CROI 2011 Feb 27-March 2 Boston
Anthony Mills,1 Andrea Antinori,2 Bonaventura Clotet,3 Martin Fisher,4 Jan Fourie,5 Gisela Herrera,6 Charles Hicks,7 Jose Valdez Madruga,8 Simon Vanveggel,9 Marita Stevens9 1Anthony Mills MD Inc., Los Angeles, CA, USA; 2National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy; 3Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation, UAB, Barcelona, Spain;4HIV/GUM Research Department, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; 5Dr J Fourie Medical Centre, Dundee, KwaZulu Natal, South Africa; 6Hospital CIMA San Jose, San Jose, Costa Rica;7Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA; 8Centro de ReferÉncia e Treinamento DST/AIDS, Mariana-Sőo Paulo, Brazil; 9Tibotec BVBA, Beerse, Belgium